Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: kendall harmon who wrote (54156)	8/1/1999 7:49:00 PM
From: kendall harmon	Respond to of 120523

CHRX-IBD new america excerpt The company does manufacturing for 40 of the top 50 drug firms and 25 biotechs. Clients include drug giants SmithKline Beecham PLC, Pharmacia & Upjohn Inc. and Glaxo Wellcome PLC. ChiRex appeals to big drug companies and biotechs differently. Both want to get products on the market fast, but they have varying ways of doing it. The giants, which have extensive R&D and production resources, turn to their in-house teams first. In the old days, they threw everything behind one lead compound. But today's drug makers work on multiple compounds, keeping costs down by outsourcing some projects to companies like ChiRex. ''The high number of leads has led to an explosion of work,'' Griffith said. ''It's cheaper for them in the long run because the upside of being first to market is so powerful.''